New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations

Elizabeth P. Harausz; Anthony J. Garcia-Prats; James A. Seddon; H. Simon Schaaf; Anneke C. Hesseling; Jay Achar; Jonathan Bernheimer; Andrea T. Cruz; Lia D'Ambrosio; Anne Detjen; Stephen M. Graham; Jennifer Hughes; Sylvie Jonckheere; Ben J. Marais; Giovanni Battista Migliori; Lindsay McKenna; Alena Skrahina; Marina Tadolini; Peyton Wilson; Jennifer Furin

doi:10.1164/rccm.201606-1227CI

New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations

Elizabeth P. Harausz, Anthony J. Garcia-Prats, James A. Seddon, H. Simon Schaaf, Anneke C. Hesseling, Jay Achar, Jonathan Bernheimer, Andrea T. Cruz, Lia D'Ambrosio, Anne Detjen, Stephen M. Graham, Jennifer Hughes, Sylvie Jonckheere, Ben J. Marais, Giovanni Battista Migliori, Lindsay McKenna, Alena Skrahina, Marina Tadolini, Peyton Wilson, Jennifer Furin

Division of Rheumatology

Research output: Contribution to journal › Review article › peer-review

63 Scopus citations

Abstract

It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

Original language	English
Pages (from-to)	1300-1310
Number of pages	11
Journal	American journal of respiratory and critical care medicine
Volume	195
Issue number	10
DOIs	https://doi.org/10.1164/rccm.201606-1227CI
State	Published - May 15 2017

Keywords

Adolescent
Child
Multidrug-resistant tuberculosis
Mycobacterium tuberculosis
Pediatric

Access to Document

10.1164/rccm.201606-1227CI

Cite this

Harausz, E. P., Garcia-Prats, A. J., Seddon, J. A., Schaaf, H. S., Hesseling, A. C., Achar, J., Bernheimer, J., Cruz, A. T., D'Ambrosio, L., Detjen, A., Graham, S. M., Hughes, J., Jonckheere, S., Marais, B. J., Migliori, G. B., McKenna, L., Skrahina, A., Tadolini, M., Wilson, P., & Furin, J. (2017). New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations. American journal of respiratory and critical care medicine, 195(10), 1300-1310. https://doi.org/10.1164/rccm.201606-1227CI

@article{4c34b7ad33784476ac93fb161f3f4726,

title = "New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations",

abstract = "It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.",

keywords = "Adolescent, Child, Multidrug-resistant tuberculosis, Mycobacterium tuberculosis, Pediatric",

author = "Harausz, {Elizabeth P.} and Garcia-Prats, {Anthony J.} and Seddon, {James A.} and Schaaf, {H. Simon} and Hesseling, {Anneke C.} and Jay Achar and Jonathan Bernheimer and Cruz, {Andrea T.} and Lia D'Ambrosio and Anne Detjen and Graham, {Stephen M.} and Jennifer Hughes and Sylvie Jonckheere and Marais, {Ben J.} and Migliori, {Giovanni Battista} and Lindsay McKenna and Alena Skrahina and Marina Tadolini and Peyton Wilson and Jennifer Furin",

note = "Publisher Copyright: Copyright {\textcopyright} 2017 by the American Thoracic Society.",

year = "2017",

month = may,

day = "15",

doi = "10.1164/rccm.201606-1227CI",

language = "English",

volume = "195",

pages = "1300--1310",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

number = "10",

}

Harausz, EP, Garcia-Prats, AJ, Seddon, JA, Schaaf, HS, Hesseling, AC, Achar, J, Bernheimer, J, Cruz, AT, D'Ambrosio, L, Detjen, A, Graham, SM, Hughes, J, Jonckheere, S, Marais, BJ, Migliori, GB, McKenna, L, Skrahina, A, Tadolini, M, Wilson, P & Furin, J 2017, 'New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations', American journal of respiratory and critical care medicine, vol. 195, no. 10, pp. 1300-1310. https://doi.org/10.1164/rccm.201606-1227CI

TY - JOUR

T1 - New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations

AU - Harausz, Elizabeth P.

AU - Garcia-Prats, Anthony J.

AU - Seddon, James A.

AU - Schaaf, H. Simon

AU - Hesseling, Anneke C.

AU - Achar, Jay

AU - Bernheimer, Jonathan

AU - Cruz, Andrea T.

AU - D'Ambrosio, Lia

AU - Detjen, Anne

AU - Graham, Stephen M.

AU - Hughes, Jennifer

AU - Jonckheere, Sylvie

AU - Marais, Ben J.

AU - Migliori, Giovanni Battista

AU - McKenna, Lindsay

AU - Skrahina, Alena

AU - Tadolini, Marina

AU - Wilson, Peyton

AU - Furin, Jennifer

PY - 2017/5/15

Y1 - 2017/5/15

N2 - It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

AB - It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

KW - Adolescent

KW - Child

KW - Multidrug-resistant tuberculosis

KW - Mycobacterium tuberculosis

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=85019879034&partnerID=8YFLogxK

U2 - 10.1164/rccm.201606-1227CI

DO - 10.1164/rccm.201606-1227CI

M3 - Review article

C2 - 27854508

AN - SCOPUS:85019879034

SN - 1073-449X

VL - 195

SP - 1300

EP - 1310

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

IS - 10

ER -

New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this